A Phase 3, Randomized, Double-blind Study Of Pf-05280586 Versus Rituximab For The First-line Treatment Of Patients With Cd20-positive, Low Tumor Burden, Follicular Lymphoma
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms REFLECTIONS
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 18 May 2017 Planned End Date changed from 27 Jun 2018 to 4 May 2018.
- 18 May 2017 Planned primary completion date changed from 21 Dec 2017 to 30 Oct 2017.